Chinese expert consensus on selective internal radiation therapy with yttrium-90 for primary and metastatic hepatocellular carcinoma.
10.3760/cma.j.cn501113-20210302-00103
- Collective Name:Nuclear Medicine Committee, Chinese Society of Clinical Oncology;;Beijing Nuclear Medicine Quality Control and Improvement Center
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Microsphere;
Selective internal radiation therapy;
Yttrium-90
- MeSH:
Carcinoma, Hepatocellular/radiotherapy*;
China;
Consensus;
Humans;
Liver Neoplasms/radiotherapy*;
Microspheres;
Yttrium Radioisotopes
- From:
Chinese Journal of Hepatology
2021;29(7):648-658
- CountryChina
- Language:Chinese
-
Abstract:
Liver malignant tumors are one of the most common causes of cancer-related deaths in China. Selective internal yttrium-90 radioembolization therapy ((90)Y-SIRT) is a kind of promising local minimally invasive method, and its effectiveness and safety has been confirmed in clinical application over the past two decades. Moreover, it has been approved by the U.S. National Comprehensive Cancer Network and other international guidelines for the topical treatment of patients with liver malignancies. Taking into account the complexity of the (90)Y-SIRT and the need for multidisciplinary collaboration to improve the safety and success rate of treatment, the Nuclear Medicine Expert Committee of the Chinese society of Clinical Oncology, along with Beijing Nuclear Medicine Quality Control and Improvement Center invited experts from surgical oncology, interventional medicine, nuclear medicine, and other related fields to discuss and form a consensus on the clinical diagnosis, treatment and management, which mainly included definition, indications and contraindications, treatment procedures, postoperative follow-up, adverse reactions and complications, radiation safety management, etc. Herein, we provide the reference guidance to establish (90)Y-SIRT standardized management and treatment system various units for relevant practitioners.
